Compare VTS & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | XOMA |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.9M | 795.5M |
| IPO Year | 2022 | N/A |
| Metric | VTS | XOMA |
|---|---|---|
| Price | $15.72 | $41.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $20.00 | ★ $52.50 |
| AVG Volume (30 Days) | ★ 603.3K | 267.2K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,989,000.00 | N/A |
| Revenue This Year | $5.48 | $24.59 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $15.01 | $22.29 |
| 52 Week High | $27.15 | $45.22 |
| Indicator | VTS | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 34.38 |
| Support Level | $15.22 | $37.00 |
| Resistance Level | $16.21 | $42.39 |
| Average True Range (ATR) | 0.44 | 0.95 |
| MACD | 0.09 | -0.10 |
| Stochastic Oscillator | 62.50 | 7.52 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.